Mark Mirochnick

2.7k total citations
61 papers, 2.0k citations indexed

About

Mark Mirochnick is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mark Mirochnick has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Infectious Diseases, 20 papers in Pediatrics, Perinatology and Child Health and 17 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mark Mirochnick's work include HIV/AIDS drug development and treatment (36 papers), HIV/AIDS Research and Interventions (32 papers) and Pregnancy and Medication Impact (17 papers). Mark Mirochnick is often cited by papers focused on HIV/AIDS drug development and treatment (36 papers), HIV/AIDS Research and Interventions (32 papers) and Pregnancy and Medication Impact (17 papers). Mark Mirochnick collaborates with scholars based in United States, Thailand and United Kingdom. Mark Mirochnick's co-authors include Edmund V. Capparelli, Barry Zuckerman, Brookie M. Best, Mary Glenn Fowler, Tim R. Cressey, Terry Fenton, Philippa Musoke, J. Brooks Jackson, Lynne Mofenson and Susan H. Eshleman and has published in prestigious journals such as PEDIATRICS, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Mark Mirochnick

61 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Mirochnick United States 25 1.2k 633 516 511 423 61 2.0k
Natella Rakhmanina United States 21 836 0.7× 338 0.5× 351 0.7× 128 0.3× 281 0.7× 95 1.3k
M Pang China 15 477 0.4× 347 0.5× 381 0.7× 249 0.5× 272 0.6× 27 1.9k
Marco Floridia Italy 19 935 0.8× 115 0.2× 373 0.7× 156 0.3× 362 0.9× 99 1.2k
John R. Koethe United States 32 2.0k 1.7× 144 0.2× 1.1k 2.1× 137 0.3× 655 1.5× 140 3.6k
Ana Milinkovic Spain 25 1.4k 1.2× 101 0.2× 771 1.5× 121 0.2× 818 1.9× 70 2.3k
Joel A. Dave South Africa 22 537 0.5× 100 0.2× 260 0.5× 111 0.2× 413 1.0× 65 1.4k
James Okuma United States 18 333 0.3× 236 0.4× 113 0.2× 149 0.3× 217 0.5× 41 864
Renate Strehlau South Africa 21 800 0.7× 80 0.1× 515 1.0× 79 0.2× 177 0.4× 84 1.2k
Amie L. Meditz United States 23 1.0k 0.9× 57 0.1× 1.1k 2.1× 96 0.2× 618 1.5× 33 2.5k
Hélène Chappuy France 19 287 0.2× 337 0.5× 71 0.1× 310 0.6× 190 0.4× 57 950

Countries citing papers authored by Mark Mirochnick

Since Specialization
Citations

This map shows the geographic impact of Mark Mirochnick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Mirochnick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Mirochnick more than expected).

Fields of papers citing papers by Mark Mirochnick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Mirochnick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Mirochnick. The network helps show where Mark Mirochnick may publish in the future.

Co-authorship network of co-authors of Mark Mirochnick

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Mirochnick. A scholar is included among the top collaborators of Mark Mirochnick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Mirochnick. Mark Mirochnick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Denti, Paolo, Roeland E. Wasmann, Helen McIlleron, et al.. (2021). One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. The Lancet Child & Adolescent Health. 6(1). 9–10. 9 indexed citations
2.
Kreitchmann, Régis, Alice Stek, Brookie M. Best, et al.. (2021). Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. Contraception. 105. 67–74. 3 indexed citations
3.
Clarke, Diana F., Edward P. Acosta, Jiajia Wang, et al.. (2020). Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(5). 626–634. 1 indexed citations
4.
Momper, Jeremiah D., Natella Rakhmanina, Dionna J. Green, et al.. (2020). Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 59(11). 1433–1450. 20 indexed citations
5.
Ruel, Theodore, Edmund V. Capparelli, Camlin Tierney, et al.. (2020). Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. The Lancet HIV. 8(3). e149–e157. 5 indexed citations
6.
Sheffield, Jeanne S., David Siegel, Mark Mirochnick, et al.. (2014). Designing Drug Trials: Considerations for Pregnant Women. Clinical Infectious Diseases. 59(suppl_7). S437–S444. 78 indexed citations
7.
Cressey, Tim R., Saı̈k Urien, Edmund V. Capparelli, et al.. (2014). Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. Journal of Antimicrobial Chemotherapy. 70(1). 217–224. 9 indexed citations
8.
Kreitchmann, Régis, Brookie M. Best, Jiajia Wang, et al.. (2013). Pharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of Pregnancy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(1). 59–66. 31 indexed citations
9.
Clarke, Diana F., Ronald J. Wong, Larissa Wenning, David K. Stevenson, & Mark Mirochnick. (2013). Raltegravir In Vitro Effect on Bilirubin Binding. The Pediatric Infectious Disease Journal. 32(9). 978–980. 17 indexed citations
10.
Mirochnick, Mark, Taha E. Taha, Régis Kreitchmann, et al.. (2013). Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(1). 33–41. 57 indexed citations
11.
Fogel, Jessica M., Taha E. Taha, Jin Sun, et al.. (2012). Stavudine Concentrations in Women Receiving Postpartum Antiretroviral Treatment and Their Breastfeeding Infants. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(5). 462–465. 5 indexed citations
12.
Fogel, Jessica M., Anthony Mwatha, Paul Richardson, et al.. (2012). Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants. The Pediatric Infectious Disease Journal. 32(4). e164–e169. 30 indexed citations
13.
Gill, Christopher, Nicholas Guerina, Chanda Mulenga, et al.. (2011). Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study. BMJ. 342(feb03 2). d346–d346. 127 indexed citations
14.
Shapiro, Roger, Diane T. Holland, Edmund V. Capparelli, et al.. (2005). Antiretroviral Concentrations in Breast‐Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment. The Journal of Infectious Diseases. 192(5). 720–727. 86 indexed citations
15.
Mirochnick, Mark & Edmund V. Capparelli. (2004). Pharmacokinetics of Antiretrovirals in Pregnant Women. Clinical Pharmacokinetics. 43(15). 1071–1087. 121 indexed citations
16.
17.
Jackson, J. Brooks, Graziella Becker‐Pergola, Laura Guay, et al.. (2000). Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 14(11). F111–F115. 163 indexed citations
18.
Vinci, Robert J., Susan S. Fish, & Mark Mirochnick. (1999). Cocaine absorption after application of a viscous cocaine-containing TAC solution. Annals of Emergency Medicine. 34(4). 498–502. 5 indexed citations
19.
Mirochnick, Mark, Terry Fenton, Paul Gagnier, et al.. (1998). Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates. The Journal of Infectious Diseases. 178(2). 368–374. 160 indexed citations
20.
Rich, Josiah D. & Mark Mirochnick. (1996). Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagnostic Microbiology and Infectious Disease. 24(2). 77–79. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natella Rakhmanina Breakdown of academic impact, for papers by M Pang Breakdown of academic impact, for papers by Marco Floridia Breakdown of academic impact, for papers by John R. Koethe Breakdown of academic impact, for papers by Ana Milinkovic Breakdown of academic impact, for papers by Joel A. Dave Breakdown of academic impact, for papers by James Okuma Breakdown of academic impact, for papers by Renate Strehlau Breakdown of academic impact, for papers by Amie L. Meditz Breakdown of academic impact, for papers by Hélène Chappuy
Rankless by CCL
2026